Bevacizumab Biosimilars Market Share, Global Industry Size, Trends, Technology, and Analysis by 2035
I recently came across a report by Roots Analysis that really put things into perspective. According to them, Bevacizumab is VEGF-A targeting, humanized monoclonal antibody-based therapeutic developed by Genentech and Roche. It was the first angiogenesis inhibitor drug to be approved by the US FDA. AvastinĀ® was first approved for treatment of advanced colon cancer (2004).
Read More :- https://www.rootsanalysis.com/....reports/avastin-bios


